Hunan Huateng Pharmaceutical Co., Ltd. (hereafter called Huateng Pharma), founded in August 2013, is a high-tech enterprise dedicated to the research and development and production of high-end biomedical chemical products, as well as the development of precision-targeted anti-tumor drugs. The company develops and produces thousands of products, including monodisperse and polydisperse PEG derivatives, high-end biochemical reagents, pharmaceutical intermediates, APIs, preparations and targeted anti-tumor drugs.
Huateng Pharma is committed to the development, manufacturing, marketing, and distribution of high-end biomedical products to clients worldwide. In 2020, a comprehensive production base built with an investment of 350 million yuan in Wangcheng Tongguan Park has been completed and put into production. The production base has fully realized intelligent and large-scale production, equipped with modern multi-functional production workshops and storage centers, 100,000-class dust-free standard clean rooms, and more than 800 sets of high-end sophisticated advanced equipment and management facilities. The production base can achieve annual sales revenue of RMB 1 billion.
Huateng Pharma undertook the Sustainable Release Drug R&D International Summit for three consecutive years from 2017 to 2019, and participated in CPHI exhibitions in various countries over the years. In 2019, we received a round A financing of RMB 60 million led by Bo Yi Fund under Tasly.
Huateng Pharma always insists on technological innovation as its core competitiveness. And the company is committed to providing high-quality pharmaceutical products and services to global customers, and making outstanding contributions to the development of human medicine and health!